Live from ASH 2024 | Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax
ROCKVILLE,Md. andSUZHOU,China,Dec. 10,2024-- Ascentage Pharma (6855.HK),a global biopharmaceutical company engaged in discovering,developing,and commercializing therapies to address global unmet medi